The live chat 31 July about the clinical trials, future research, and treatments with cord blood in Russia

Link to lisen interview

Dr. Olga Tyumina is the President of Ruscord, a non-profit organization of specialists and organizations in the field of procurement, storage and use of umbilical cord blood and cellular technologies. Dr. Tyumina is a prominent doctor in medical sciences, professor of the Russian Academy of Sciences, honored health worker in the Samara Region (Russia), and the Director of the Samara Regional Medical Center, Dynasty. She is the author of 120 publications and holds multiple patents, registered computer programs and monographs.

Dr. Stanislav Volchkov is the Deputy Director of the Samara Regional Medical Center, Dynasty, the Executive Director of the non-profit Hematopoietic Progenitor Cells Registry, Expert of the Fund for Assistance to Small Innovative Enterprises in Science and Technology, Founder of the Institute of Biotechnology and Pharmacology Inbiopharma, LLC, and is a certified designee for biomedical cellular products acquired by Ministry of Health of the Russian Federation.

In this live chat we will discuss the clinical trials, future research, and treatments currently provided at the Center of Cellular Technologies in Samara (Russia) using donor cord-blood transfusions and other stem cell therapies for the treatment of Autism, Cerebral Palsy and other developmental disorders.

Duke study for ASD children’s with allogenic and autologous cord blood

Interview : by Enrique Basurto :

Link to lisen:

Key takeaways from our live interview with Dr. Joanne Kurtzberg today re. the results of the phase-II trial using cord-blood infusions in children with Autism,

1. As noted in the Discussion section of the publication, the research Team believes that the lower than needed sample of children with non-verbal IQ > 70 might have compromised the results of the study. However, although the study did not meet the target outcome (as measured by the Vineland socialization scale), there were statistically significant improvements in the higher non-verbal IQ (NVIQ) cohorts particularly in 4-to-7 y.o. in communication scales, eye tracking and EEG

2. Currently, there are 3 stem cell studies for Autism where the Duke Team is involved: a) Using cord tissue MSCs (where 500-1,000 doses could be extracted from a single cord and therefore multiple infusions could be received) with 4-to-7 year olds with NVIQ > 70 (with NVIQ measured at Duke as opposed to remotely in order to -hopefully- ensure statistical significance next time). b) A study in China aiming at diagnosing and treating Autism using cord-tissue infusions earlier in life. c) A small trial with ASD adults ages 18 to 35. These 3 trials are already funded but currently on hold due to COVID-19 but are expected to resume ASAP. Dr. Kurtzberg noted that in the future, it is possible that a combination of multiple stem cell sources could show higher efficacy than any individual source could achieve on its own, e.g. starting with a cord-blood infusion followed by cord-tissue MSCs infusions every 3-6 months to sustain benefits

3. In order to get FDA-approval for cord-blood infusions in the US, it is necessary to show definite benefit in a phase-III randomized placebo controlled trial. To that effect, the Duke Team believes that the results from the phase-II trial are compelling enough to seek funding for a phase-III trial with cord blood infusions in 4-to-7 year olds with NVIQ > 70. (As a side note, limiting the sample to 4-7 y.o. with NVIQ > 70 does not mean that lower functioning children could not benefit from cord-blood infusions, that is simply to delineate the inclusion criteria that is most likely to demonstrate benefits in the shortest amount of time)

4. During the course of the phase-II trial, the vast majority of parents who « guessed » when their children had received the cord-blood infusion (as opposed to the placebo) based on the improvements they observed in behaviors, focus, concentration, socialization, testing and communication (by ether increasing their vocabulary or by appropriately using the words they had) were correct. OTOH, The placebo effect was reportedly higher than expected, part of the reason why this could have happened was due to the tools used to assess improvements in 2-to-4 year olds, specially given the fact that this is an age where children in general could potentially acquire various skills

5. In principle, it is possible to get FDA-approval for an expanded access program using donor cord-blood infusions for children with Autism. However, the waiting list for the autologous infusions already surpasses the capacity of the Team at Duke. That said, Duke is currently working with a few other clinics/centers/hospitals to open up expanded access programs around the US (e.g. MD Anderson, Rutgers, etc.) that can provide access to cord-blood infusions without the long waiting lists

6. Although MSCs can be manufactured from adipose tissue or from the bone marrow, based on several studies, Dr. Kurtzberg believes MSCs from umbilical cord tissue are more potent. That said, studies using MSCs using bone marrow have also shown positive outcomes in Autism. Dr. Kurtzberg mentioned exosomes are controversial and have not been studied as much as MSCs. MSCs activate macrophages so the use of exosomes without MSCs may not cause the kind of benefits compared to when MSCs are present

7. Regarding prep work, the research Team has not found any indication that diets, supplements or other biomedical treatments can increase that chance of success from stem cell therapy

8. In theory, infusing HLA-matched (or partially HLA-matched) cord-blood in a recipient should increase the amount of time that the donor cells can survive in the recipient’s body. Also, by infusing HLA-matched cord blood there is less chance of « sensitizing » the recipient’s system against foreign HLA which could potentially make the recipient develop antibodies that could limit the donor base later in life if transfusions were needed for other reasons

Publication ->

#AutismIsMedical #AutismIsTreatable #1in54 #FlattenTheAutismCurve #AutismPandemic #TheRealPandemic

« In a subanalysis of children without intellectual disability (ID), allogeneic, but not autologous, CB was associated with improvement in a larger percentage of children on the clinician-rated Clinical Global Impression-Improvement scale”

And: “Children without ID treated with CB showed significant improvements in communication skills (VABS-3 Communication Domain), and exploratory measures including attention to toys and sustained attention (eye-tracking) and increased alpha and beta electroencephalographic power.”

“The rationale is that CB CD14+ monocytes act through paracrine signaling to modulate brain inflammation and/or immune abnormalities, improving brain function and behavior.”

“One hundred eighty children, aged 2-7 years (mean ± SD, 5.47 ± 1.65) who met DSM-5 criteria for ASD participated. Diagnosis was based on the Autism Diagnostic Observation Schedule-217 and Autism Diagnostic Interview, Revised.18 Participants were screened for a genetic cause of ASD with testing for Fragile X and chromosomal microarray. Inclusion criteria included (1) negative genetic testing, (2) qualified CB unit with a minimum banked total nucleated cell dose of ≥2.5 × 107 cells/kg or ≥4/6 HLA-matched allogeneic unrelated CB unit, (3) stable on medications for ≥2 months, (4) ability to travel to study site twice, (5) English speaking, and (6) normal absolute lymphocyte count (≥1500/μL).”

But : “Infused dose was not associated with the primary and secondary outcomes, with the exception of the CGI. The allogeneic cohort received a higher TNC dose compared with the autologous cohort (3.8 × 107/kg vs 2.7 × 107/kg) making it impossible to determine whether the effect in the allogeneic group was due to the higher cell dose or to CB type.”

“When participants with NVIQ ≥70 were analyzed separately, the results indicated that participants without ID who were treated with CB exhibited significantly increased relative alpha powerposterior/toys (P = .02) and significantly increased relative beta1 powerall brain regions/social (P = .02) compared with the placebo group (Figure 5). No main effects were found for theta or gamma power.”

“However, for children without ID, clinician CGI ratings indicated that children treated with allogeneic CB, but not those treated with autologous CB, showed improvement over placebo. Children without ID also showed significantly greater improvement in a prespecified secondary outcome measure of VABS Communication SS when treated with CB compared with placebo.”

EXO serum or haw I found best cream for me while studying cord blood ….

Exosomes derived from human umbilical cord blood mesenchymal stem cells stimulates rejuvenation of human skin!!!!

And :

Denise Serigny my mother in law send me her testimonial for EXO: (she does not have Facebook now) and she is 78 years old!

But this is her experience after 6 months:

“What a pleasure to put on my face, morning and evening, this little drop of EXO.

Immediately i felt my skin becomes “full” of this elixir and in a few seconds nourishes and beautifies it.

I always thought, that i will become “old » in natural way… I would never resort to cosmetic surgery, I want to keep on my face the traces of my history.

EXO, suits me fully : gradually reducing fine wrinkles and slightly filling the skin , giving it a « healthy glow » effect.”

Description EXO :–OoUmNIMMub0aAzZp2pYPue05NQsdrU0cEdHQfuBPzHTspduQb5KtCVEefB6OOPLoMtKEE8kXRMaLt3NtgjreeZe

A lot of friends ask me how to maintain youth and look good at my age (I’m 46 on the left of photo) …so ….honestly, I think several factors play a role …

Of course genetics; nutrition and physical activity … but for the skin …. not only …. my friends often ask me what cream I use …. I honestly did not use any;) before….but recently we drove to treat our son brain injury in Samara and there I found a cream on a natural basis – based on exosomes ….from umbilical cord blood .. (I studed a lot of scientific literature on umbilical cord blood as you can find in previous articles on my blog….for my son and therefore I know a lot about its capabilities) therefore it was this serum with exosomes that I personally was interested to give a try and honestly the result on my face became already visible after 2 months!

I can testify that after 8 months of treatment an excellent result on my face skin really great some wrinkles are less visible (but the result is absolutely natural) not like the stretched and inflated faces of Botox stars …oh … the horror … 😂

I am 46 years old, and I am very pleased with EXO serum, it is effective, soft and natural – and, in my opinion, it is ideal (I am not a supporter of Botulique toxins and not a supporter of plastic surgeries – I consider this exagération – in pursuit of “rejuvenation” and results …. haw to say – better to use in horror films- very unnatural and doubtful …. and it could harm your health ! Botox can harm you it’s toxic…..

Of cause at the same time, as any woman I’m looking for a way to stay attractive – but as “natural” as possible and therefore I personally really like EXO Serum.

It should be noted that this is not just external beauty, but also real skin health and restoration of skin functions! So very very healthy !!!!

Exosomes of umbilical cord mesenchymal cells have proven effective for skin rejuvenation in preclinical studies by a group of scientists from the USA and China. Experiments have shown that exosomes can potentially be used to regenerate and rejuvenate the skin with various defects. The work was published in ACS Omega magazine:

Exosomes have the ability to stimulate the proliferation of dermal fibroblasts, as well as enhance their production of collagen, elastin and fibronectin.

As I wrote earlier, EXO underwent research in Samara for burns and healing wounds.

Everything was perfectly explained long ago in the video:

I buy my face EXO serum in Russia! I live in france but I prefer this serum than any other big French marks of face creams and serums….


You want to see files find more videos and about see on fb page:

Human Umbilical Cord blood monocytes, rescue brain cells from hypoxic-ischemic injury:

Finally I found publication about CD14 cells in cord blood from Duke!

here Duke study about CD14 +

Cd14 in cord blood

they found potential not in perepheric blood !!!so not all cd14 are equal :

« Gene expression microarray analysis demonstrated that compared to PB-CD14 monocytes, CB-CD14 monocytes over-expressed several secreted proteins with potential to protect neurons. Differential expression of five candidate effector molecules, chitinase 3-like protein-1, inhibin-A, interleukin-10, matrix metalloproteinase-9 and thrombospondin-1, were confirmed by western blotting, and immunofluorescence. These findings suggest that CD14 monocytes are a critical cell-type when treating HI with CB-MNC. »

« intravenously injected CB-MNC products [55] do not need to reach the brain in order to promote repair of stroke or other HI brain injury. Instead, cell products

reaching the lungs or spleen may induce endogenous cells to produce soluble factors or activated

cells that go to the brain and mediate repair [56-58]. Future studies investigating the

biodistribution of CB monocytes will determine the most effective route and dose for


In summary, monocytes in CB, but not PB, protect brain neurons from death and reduce glial

activation following HI insult in an in vitro OGD model. Soluble factors released from CB

monocytes contribute to this protection. We have identified secreted proteins enriched in CBCD14+ monocytes compared to PB monocytes that may play a role in neuroprotection and repair.

This work enables future detailed study of the mechanism of neuroprotection and development

of mechanism-based release assays for CB products, and formulation of new strategies for using

CB monocytes as therapeutic agents in treatment of HI-induced brain injuries. »

No comments

Just for anybody’s who wants to comment on my blog : I am not confirming ANY comments on it I had too much spam messages and I don’t have time to see all comments which is good or spam … so I delate every day ALL COMMENTS send me

Sorry for your inconvenience but it’s like this

If you want to contact me ( not spam) send me mail:

And I will see if it’s really professional mail or just a spam ( haw to create my blog and not about nerologie – all spam I put in garbage !!!)

My blog is free I am not gaining money from it I don’t have time for useless comments.

Thanks for understanding

Book /Livre

Voilà mon livre « Marc L’invincible » est désormais en ligne et disponible* à l’achat dans la boutique Kindle: ( en français)

« Marc L’invincible: L’histoire vraie d’une récupération remarquable, après arrêt cardiaque et lésions cérébrales anoxiques », est désormais disponible en livre broché dans la boutique Amazon. Les lecteurs peuvent l’acheter:

Here is my book « Marc L’invincible » is now online and available * for purchase in the Kindle store: (in French)

I will do English translation ( just give me some time)

Ici lien vers page de Écrivain-biographe basée à Grenoble -Membre des Compagnons Biographes – Julie Lucquet qui à prêter son plume pour raconter notre histoire :

Cord blood or MSC ?

Just 2 very interesting studies :

1) « behavioural deficit was significantly improved with multiple doses of cord blood, but not with a single dose. We also showed that the injury caused significant loss of brain tissue and cell death, which was only improved in the study arm that administered multiple doses of cord blood cells. “


And second :

2) This was made on animal model but UCB seems to be batter choice than MSC….

So a lot to think….

« This study is the first to compare the neuroprotective efficacy ofUCB cells versus MSCs for inflammation-induced preterm braininjury. Both UCB cells and MSCs have protective benefits for thepreterm brain, but their effects on white matter are different.MSCs were strongly anti-inflammatory, dampening multipleindices of brain inflammation at the cellular and gene level. Incontrast, UCB cells showed a reduced ability to mediateneuroinflammation, but importantly, prevented apoptosis-mediated cell death and protected mature myelinating oligoden-drocytes. These differential effects of UCB and MSCs are likely dueto specific actions of an isolated cell population (MSCs) versus astem/progenitor cell mix (UCB). «


In response to LPS-induced preterm brain injury, administration of

MSCs had a global effect on dampening brain inflammation,

which in turn may have detrimental effects on brain repair and

normal development. MSCs did not improve survival of critical

oligodendrocytes and did not prevent apoptosis-mediated cell

death. In contrast, UCB was neuroprotective against cell death and

normalized the number of mature myelinating oligodendrocytes, but did not display the same anti-inflammatory effects as MSCs.

Our results indicate that UCB is a more comprehensive therapy for

protecting white matter brain development, likely contributed by

the mixed cell population in UCB, and their differential actions. »

thé problème i think we need be very careful with dosing MSC:

« In contrast, MSCs require expansion by tissue culture

and are a much larger cell (average 25 μm), limiting the

concentration that can be administered in a single dose without

risk of embolism. »


« Therefore, a global dampening of inflammatory mediators with MSC administration (as seen in the directional change of the bars

in Fig. 4) may interrupt normal brain development and it may be

such that reducing an aberrant pro-inflammatory cerebral

response with cell treatment is preferable. MSC treatment

decreased white matter expression of IGF-1, which is essential

for normal oligodendrocyte maturation produced by multiple cell

types within the CNS, particularly the glial cells.

Indeed, IGF-1 is

proposed as a rescue therapy for hypomyelination,

and protective for oligodendrocytes. »

« The dampening of inflammation and growth factor expression

by MSCs may be a concern, further investigation into this finding

is required. »

Here’s the video of Dr. Kurtzberg speaking at the New Horizon Arizona Stem Cells conference -April 2019

Here’s the video of Dr. Kurtzberg speaking at the New Horizon Arizona Stem Cells conference :

(April 2019)

7:30mins discuss male cells getting into brain of CP

Hydrocortisone reduces fevers

12mins starts to talk about autism

19mins only male donors for the cord tissue trial are being used but doesn’t mention if male are better than female. Taken from c-section babies (interesting as c-section implies potential complications). They expand the cells to passage 2. Each cord produces about 60billion expanded cells, amounting to 60 to 100 doses (@ 2million cells per kilo).

23mins one child didn’t use Benadryl and started coughing from transfusion, resolved with the use of Benadryl.

25:40mins hypoxic brain injury helped with cord blood. But beneficial effects stopped when CD14 cells are removed!

33mins slide with cell characteristics for CP trial.

36mins gross motor improvements seen in CP study. Higher doses showed better results. Would love to know what the higher dose is versus the smaller dose.

40:40mins suggesting a cord blood transfusion followed by an MSC booster.

47mins they have over 2000 families on their wait list which is over a years work for them.

If you can’t see hole video on my Facebook please try on YouTube ( I separated in 3 parts):

Part 1:

Part 2:

Part 3:

And I will put all power points Photos ( sorry not in in order of presentation):

CD14 cells in cord blood that is special and helps repair brain cells from low oxygen in brain or hypoxic injury

About stem cells :

Watch this dr Kurtzberg presentation ( in English from 12 minutes)

From the 20:54, Dr Joanne Kurtzberg says It’s the CD14 cells in cord blood that is special and helps repair brain cells from low oxygen in brain or hypoxic injury

And as I know nobody doing yet hole donor cord blood HLA matched exept Duke ( and yet in clinical trails)….

More on Dr Kurtzberg’s presentation of the good monocytes in cord blood cells:

10:38 [Referring to cord blood cells]…and about 10% are a kind of cells called the monocyte. Monocyte in cord blood is unique and it’s the cell that we think is helping patients with cp and autism. And we don’t think it’s helping because it’s engrafting in the brain or turning into neurons or turning into brain cells. We think it’s helping because it puts out chemicals that signal cells that’s already in the brain to repair damage.

human UCB (hUCB) is a complex internal environment rich in a variety of stem/progenitor cell populations, such as hematopoietic stem cells (HSCs), endothelial progenitor cells (EPCs), UCB monocytes (including T regulatory cells (Tregs) and monocyte-derived suppressor cells (MDSCs)) and MSCs…etc….

UCB mononuclear/ whole blood cells in the perinatal ischemic and hypoxic brain model can reduce the inflammatory response to treat injury. To evaluate whether transplanted cells relieve neuroinflammation, there are two indicators:

(1) reduce the infiltration of CD4 þ T cells into the brain; and (2) reduce microglial activation.

all UCB cell types except EPCs have CNS immunoregulatory capacity.

Tregs and monocytes are present in the normal body at a considerable level, and are indispensable in the regulation of peripheral and central immune responses.

« Currently, the use of UCB-based interventions for CP is limited as the components of UCB are complex and possess different therapeutic mechanisms. These can be categorized by three aspects: homing and neuroregeneration, trophic factor secretion, and neuroprotective effects. »

There are several paper about cord blood CD14+ cells neuroprotective action ( CB Monocytes – CD14+ cells protect brain cells from Oxygen and Glucose Deprivation in Cortex). Even more: cord blood cells contain many neurotrophic factors, which are very important for brain regeneration.

•Brain-derived neurotrophic factor,

Nerve growth factor-

•Neurotrophin-3 –

•Neurotrophin-4 –

•Glial cell-derived neurotrophic factor –

•Cerebral dopamine neurotrophic factor –

•Mesencephalic astrocyte-derived neurotrophic factor

•Pigment epithelium-derived factor.

Latest Duke publication about CD14: